A new vaccine to provide teens and young adults protection against a deadly strain of meningococcal disease has been launched in Australia.
The meningococcal B vaccine Trumenba is now available for the immunisation of people 10 years and older, made by manufacturer Pfizer.
While rare, meningococcal disease can strike without warning, killing up to one in ten, and leaving up to a third of survivors with damaging after-effects ranging from psychological disorders to loss of limbs.
For the past 30 years meningococcal group B (MenB) has been one of the most prevalent strains of the disease in Australia.
Professor Robert Booy, Head of Clinical Research at the National Centre for Immunisation Research and Surveillance (NCIRS) warns the disease has become more common in the last three years.